Compare ARK Genomic Revolution ETF (ARKG) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Lowe`s Companies Inc — how do they compare? ARK Genomic Revolution ETF trades at $41, while Lowe`s Companies Inc trades at $212.03 (market cap $118.66B). The key difference: Lowe`s Companies Inc pays a 2.36% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Lowe`s Companies Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | LOW | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $287.39 |
52-Week Low | $23.09 | $206.62 |
Market Cap | — | $118.66B |
Enterprise Value | — | $160.42B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Lowe's Companies (LOW) trades at $211.63, down 0.64% on the day, with a bearish technical signal from moving averages. The company maintains solid fundamentals with a P/E of 17.89 and net income margin of 7.51%, having beaten earnings estimates for three consecutive quarters. Revenue declined to $83.67 billion in 2025 but shows stabilization with 2026 projections of $88.4 billion. Analyst consensus remains strongly bullish with a $260.88 price target, representing 23% upside potential from current levels.
LOW presents a compelling value opportunity with strong dividend growth and consistent earnings performance, though near-term headwinds include housing market sensitivity and competitive pressures. The stock's current valuation discount to analyst targets and improving cash flow trends support a positive medium-term outlook, balanced by technical weakness and macroeconomic uncertainties affecting the home improvement sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
